Healthy Clinical Trial
Official title:
Physiological Effects of New Polyphenol-enriched Foods in Healthy Humans
Polyphenolic compounds exert several health benefits depending on bioavailability. Encapsulation may improve bioavailability of these compounds.This study will evaluate bioavailability of some polyphenols (curcumin and cocoa polyphenols) from new enriched-foods. In particular bread and nut based creams will be used as food matrices to include free or encapsulated polyphenols.
Polyphenolic compounds are abundant in foods and have been suggested to exert several health
benefits including prevention of cancer, cardiovascular disease, suppressing inflammation,
diabetes, etc. These properties are mediated by bioavailability of individual polyphenols
that is, in turn, influenced by food properties (food matrix, technological processing,
etc.), interaction with other compounds, and host related factors. Some well-studied dietary
polyphenols include catechins from tea, curcumin from turmeric, procyanidins and
anthocyanidins in grapes, berries, and dark chocolate. These compounds have strong
antioxidative activities in vitro and have been suggested to have several beneficial health
effects.
Curcumin, a phenolic compound deriving from turmeric spice, shows many biological and
pharmacological effects, and clinical studies in humans proved that it's extremely safe and
well tolerated even at very high doses (8-12 g/day). However, curcumin has not yet been
approved as a therapeutic agent, because of its very low bioavailability depending on a poor
absorption, rapid metabolism and rapid systemic clearance. Different approaches have been
investigated to improve curcumin bioavailability. Among them, the use of adjuvants that
interferes with metabolic pathways of curcumin, like piperine, represents one of the main
strategies used to enhance its bioavailability. A further approach consists on manufacturing
of curcumin containing liposomes, phospholipids complexes or nanoparticles. For
polymer-based nanoparticles, maintenance of biological activity, increased absorption and
delayed delivery was reported.
Cocoa based products are widely consumed in many countries, and indications of health
benefits by some cocoa constituents, mainly polyphenols, have also been reported. Cocoa
contains very high levels of polyphenols, in particular flavanols and among these, mainly
epicatechins. The bioavailability of cocoa polyphenols has been measured in several human
studies from acute consumption of cocoa rich beverages or chocolate. Monomeric flavonoids as
well as dimeric and trimeric procyanidins were detected in human plasma over 2-3 hours from
consumption. Plasma concentration of cocoa polyphenols were often in the nanomolar or low
micromolar range. Donovan and coworkers demonstrated that commercial available chocolate
samples contain a predominance of the less bioavailable (-)-catechin enantiomer as compared
to the (+)-catechin which is present in most other plant derived foods. This may explain the
relatively low bioavailability of catechins from chocolate and cocoa-containing products.
The food matrix seems to be an important factor that may affect the bioavailability of cocoa
polyphenols. For instance, proteins in the food matrix are supposed to form highly
polymerized complexes with procyanidins, which can reduce bioaccessibility of these phenolic
compounds. However, the potential negative effect of protein content in foods was not
confirmed in a study that evaluated the cocoa polyphenols bioavailability after the intake
of a milk-powder cocoa beverage. However, concurrent carbohydrates consumption seems to
increase significantly the uptake of flavonols in humans. Little is known whether and to
what extent oligomeric procyanidins from cocoa are absorbed. However, the biological
activity of procyanidins with high polymerization degree may be partly attributed to their
colonic breakdown products, including phenolic acids.
Actually there is also a growing interest in other biological properties of phenolic
compounds in addition to their antioxidant effects; particularly, some evidences suggest
that certain dietary phenols may modulate metabolic homeostasis. This is the case of
chlorogenic acids, that are reported to play a potential role in modifying the pattern of
intestinal glucose uptake and of other flavonoids (quercetin, catechins) that may modulate
activation of GLP-1 receptor, involved in modulation of insulin and glucagon secretion,
gastric emptying, and appetite.
In this randomized, crossover trial, serum, urine and fecal concentrations of curcumin and
cocoa polyphenols, their parental compounds, metabolites and phenolic acids, following a two
day multi-dose administration with six food sources, will be measured. All volunteers will
undergo to six interventions - bread enriched with three different forms of curcumin (free,
encapsulated, and encapsulated plus piperine) and nut based creams enriched with cocoa
polyphenols (free or encapsulated one) or control cream (without enrichment). A one-week
wash-out period will be included between two sequential treatments. Blood, urine and feces
will be collected at time 0 (baseline), 24, and 48 hours; further blood samples at 0.5, 1,
2, 4, 6 hours after consumption of the first meal, and urine samples at 2 hours time
intervals up to 10 hours, will be collected too. In particular, area under the curve (AUC)
of serum and urine concentrations of parental compounds and metabolites in the time interval
0-24 hours will be calculated as primary outcomes. In addition the amount of total
polyphenols in fecal samples will be measured.
;
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |